2024
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart review
2023
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.Peer-Reviewed Original ResearchMeSH KeywordsCD4-Positive T-LymphocytesHumansLymphoma, T-Cell, CutaneousReceptors, Antigen, T-CellSkin NeoplasmsTranscriptomeConceptsCutaneous T-cell lymphomaMalignant CTCL cellsDiverse transcriptomic profilesT cellsSingle-cell RNACTCL cellsDevelopment of CTCLIntegrated transcriptomeT-cell receptor sequencingT cell exhaustion phenotypeCommon antigenic stimulusPeripheral blood CD4Transcriptomic profilesGene expressionT-cell lymphomaIntegrative analysisPotential therapeutic targetProliferation advantageLimited diversityBlood CD4Blood involvementMutation levelsExhaustion phenotypeWorse prognosisAntigenic stimulusProteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Xu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.Peer-Reviewed Original Research
2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracenesFemaleHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesOintmentsPerylenePhotochemotherapyPhotosensitizing AgentsSkin NeoplasmsTreatment OutcomeConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatmentPrimary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHumansLymphoma, T-Cell, CutaneousMycosis FungoidesNeoplasm StagingSezary SyndromeSkin NeoplasmsUnited StatesConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy design
2021
Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings
King ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings. Journal Of Investigative Dermatology 2021, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.Peer-Reviewed Original ResearchMeSH KeywordsHumansLymphoma, T-Cell, CutaneousPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsSkin Neoplasms
2020
Disparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion location
Mirza F, Yumeen S, Girardi M. Disparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion location. British Journal Of Dermatology 2020, 184: 170-171. PMID: 32730673, DOI: 10.1111/bjd.19426.Peer-Reviewed Original ResearchOutcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchMeSH KeywordsCell Line, TumorHistone DeacetylasesHumansLymphoma, T-Cell, CutaneousProteasome Endopeptidase ComplexProto-Oncogene Proteins c-bcl-2Skin NeoplasmsConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibitionUnited States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
Zic J, Ai W, Akilov O, Carter J, Duvic M, Foss F, Girardi M, Gru A, Kim E, Musiek A, Olsen E, Schieke S, Shinohara M, Zain J, Geskin L. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 83: 703-704. PMID: 32305443, PMCID: PMC7161526, DOI: 10.1016/j.jaad.2020.04.049.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalBetacoronavirusChemoradiotherapyCoronavirus InfectionsCOVID-19Hematopoietic Stem Cell TransplantationHome Care Services, Hospital-BasedHumansLymphoma, T-Cell, CutaneousMycosis FungoidesPandemicsPatient SelectionPhotopheresisPneumonia, ViralRisk AssessmentSARS-CoV-2Severity of Illness IndexSezary SyndromeSkin NeoplasmsTelemedicineUltraviolet TherapyUnited StatesInsights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S, Girardi M. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. The Yale Journal Of Biology And Medicine 2020, 93: 111-121. PMID: 32226341, PMCID: PMC7087059.Peer-Reviewed Original ResearchMeSH KeywordsGene ExpressionGenetic Association StudiesHumansLymphoma, T-Cell, CutaneousSignal TransductionSkin NeoplasmsConceptsGenomic copy number alterationsSingle nucleotide variantsCutaneous T-cell lymphomaCellular underpinningsJAK-STAT activationT-cell lymphomaT lymphocytesCopy number alterationsCTCL cellsSeries of alterationsWhole-exome sequencingCell lymphomaApoptosis resistanceNucleotide variantsOncogenic behaviorPathophysiology of CTCLSkin-homing T lymphocytesT cell activationCell expansionNumber alterationsCTCL pathogenesisGenetic alterationsGenomic alterationsCell-mediated immunityTherapeutic discovery
2019
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration
2018
Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity
Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity. Cancer Research 2018, 78: canres.0171.2018. PMID: 29764863, DOI: 10.1158/0008-5472.can-18-0171.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, NeoplasmAntineoplastic AgentsBlood PlateletsCell Line, TumorDendritic CellsImmunotherapyLymphoma, T-Cell, CutaneousMaleMiceMice, Inbred C57BLMonocytesPhotochemotherapyConceptsT cellsT cell antitumor immunityTumor-specific T cellsTumor cellsEffective immunotherapeutic agentFavorable safety profileResponder T cellsDendritic cell differentiationTumor-challenged miceImmunogenic cell deathSelective antitumor effectApoptotic tumor cellsPotential therapeutic applicabilityProcessing/presentationAntimelanoma immunityHealthy DCsImmunogenic malignanciesAntitumor immunityCellular vaccinesImmunotherapeutic effectsAdditional malignanciesImmunotherapeutic agentsSafety profileCancer immunotherapyTumor antigensAn Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma
Chang LW, Patrone CC, Yang W, Rabionet R, Gallardo F, Espinet B, Sharma MK, Girardi M, Tensen CP, Vermeer M, Geskin LJ. An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma. Journal Of Investigative Dermatology 2018, 138: 2681-2683. PMID: 29981755, DOI: 10.1016/j.jid.2018.06.176.Peer-Reviewed Original ResearchClinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original ResearchMeSH KeywordsAminopterinDose-Response Relationship, DrugFemaleFolic Acid AntagonistsFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedPrognosisRetrospective StudiesSkin NeoplasmsPillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609.
Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609. The Journal Of Immunology 2018, 200: 3031-3035. PMID: 29685949.Peer-Reviewed Original ResearchAnimalsHistory, 21st CenturyHumansLymphoma, T-Cell, CutaneousReceptors, Antigen, T-Cell, gamma-deltaSkin NeoplasmsT-Lymphocytes
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategiesPrimary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.Peer-Reviewed Original ResearchSynergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors